Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.79 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.79 |
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669862 | 1.00 | ADORA3 (0.79) | ADORA3ADORA1ADORA2AADORA2BTYMP | |
| SCHEMBL7732648 | 0.89 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BTYMP | |
| SCHEMBL7732645 | 0.89 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BTYMP | |
| SCHEMBL6661428 | 0.88 | ADORA3 (0.86) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6664819 | 0.88 | ADORA3 (0.86) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6671297 | 0.86 | ADORA3 (0.75) | ADORA3ADORA1ADORA2AADORA2BDNPH1 | |
| SCHEMBL7064170 | 0.86 | ADORA1 (0.71) | ADORA3ADORA1ADORA2AADORA2BDNPH1 | |
| SCHEMBL7064173 | 0.86 | ADORA1 (0.71) | ADORA3ADORA1ADORA2AADORA2BDNPH1 | |
| SCHEMBL7064432 | 0.82 | ADORA3 (0.63) | ADORA3ADORA1DNPH1ALDH1A1LMNA | |
| SCHEMBL7064426 | 0.82 | ADORA3 (0.63) | ADORA3ADORA1DNPH1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008842-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-09 | — | — | US | claimed |
| EP-1239883-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| EP-1239880-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001045684-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| WO-2001045686-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1239879-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1239878-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT1 AGONISTS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | disclosed |
| US-20030008842-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-09 | — | — | US | disclosed |
| US-20030004126-A1 | Formulations of adenosine A1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20030004129-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| WO-2001045714-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045682-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045684-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045686-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045715-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018008-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA3, ADORA2A | ADORA3 2/4885ADORA1 1/4885ADORA2A 3/4885 |
| US-20030004126-A1 | Formulations of adenosine A1 agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
| US-20030004129-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
| US-20030008842-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA2B, ADORA2A | ADORA3 4/4885ADORA1 1/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.